Multi-ligand poly(l-lactic-co-glycolic acid) nanoparticles inhibit activation of endothelial cells

Journal of Cardiovascular Translational Research

Volumn 6, Issue 4, 2013, Pages 570-578

  Xu, Hao ^a   Kona, Soujanya ^b   Su, Lee Chun ^b   Tsai, Yi Ting ^b   Dong, Jing Fei ^c   Brilakis, Emmanouil S ^a   Tang, Liping ^b   Banerjee, Subhash ^a   Nguyen, Kytai T ^b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b The University of Texas at Arlington   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Endothelial cell; Glycoprotein 1b; Nanoparticle; Trans activating transcriptional peptide

Indexed keywords

DEXAMETHASONE; GLYCOPROTEIN IB; MACROGOL; NANOPARTICLE; PADGEM PROTEIN; POLYGLACTIN; POLYMER; TRANSACTIVATING TRANSCRIPTIONAL PEPTIDE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY OCCLUSION; ARTICLE; CAROTID ARTERY INJURY; CELL ADHESION; CELL TRANSPORT; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; ENDOTHELIUM CELL; FLOW RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOLECULAR DYNAMICS; NANOENCAPSULATION; NEOINTIMA; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SHEAR STRESS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CAROTID ARTERY INJURIES; CAROTID ARTERY, COMMON; CAROTID STENOSIS; CELLS, CULTURED; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DRUG CARRIERS; ENDOTHELIAL CELLS; HUMANS; LACTIC ACID; LIGANDS; NANOPARTICLES; NEOINTIMA; P-SELECTIN; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; VON WILLEBRAND FACTOR;

RATTUS;

EID: 84880506310     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-013-9460-5     Document Type: Article

References (45)

1. Schillinger, M.; & Minar, E. (2005). Restenosis after percutaneous angioplasty: the role of vascular inflammation. Vascular Health and Risk Management, 1, 73-78.
2. Savoia, C.; & Schiffrin, E. L. (2007). Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clinical Science (London, England), 112, 375-384.
3. Munro, J. M.; & Cotran, R. S. (1988). The pathogenesis of atherosclerosis: atherogenesis and inflammation. Laboratory Investigation, 58, 249-261.
4. Zampolli, A.; Basta, G.; Lazzerini, G.; Feelisch, M.; & De Caterina, R. (2000). Inhibition of endothelial cell activation by nitric oxide donors. Journal of Pharmacology and Experimental Therapeutics, 295, 818-823.
5. Everts, M.; Kok, R. J.; Asgeirsdottir, S. A.; Melgert, B. N.; Moolenaar, T. J. M.; Koning, G. A.; et al. (2002). Selective intracellular delivery of dexamethasone into activated endothelial cells using an e-selectin-directed immunoconjugate. Journal of Immunology, 168, 883-889.
6. Versaci, F.; Gaspardone, A.; Tomai, F.; Ribichini, F.; Russo, P.; Proietti, I.; et al. (2002). Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (impress study). Journal of the American College of Cardiology, 40, 1935-1942.
7. Park YM, Han SH, Lee K, Suh SY, Oh PC, Shin EK (2013) Dexamethasone-eluting stents had sustained favorable ischemic driven target lesion revascularization rates over 5 years: a randomized controlled prospective study. International Journal of Cardiology, in press.
8. Qin, J.; Du, R.; Yang, Y. Q.; Zhang, H. Q.; Li, Q.; Liu, L.; et al. (2013). Dexamethasone-induced skeletal muscle atrophy was associated with upregulation of myostatin promoter activity. Research Veterinary Science, 94, 84-89.
9. Kim, M. H.; Lee, G. S.; Jung, E. M.; Choi, K. C.; & Jeung, E. B. (2009). The negative effect of dexamethasone on calcium-processing gene expressions is associated with a glucocorticoid-induced calcium-absorbing disorder. Life Sciences, 85, 146-152.
10. Ranta, F.; Avram, D.; Berchtold, S.; Dufer, M.; Drews, G.; Lang, F.; et al. (2006). Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes, 55, 1380-1390.
11. Davis, M. E.; Chen, Z. G.; & Shin, D. M. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Reviews. Drug Discovery, 7, 771-782.
12. Zhang, L.; Gu, F. X.; Chan, J. M.; Wang, A. Z.; Langer, R. S.; & Farokhzad, O. C. (2008). Nanoparticles in medicine: therapeutic applications and developments. Clinical Pharmacology and Therapeutics, 83, 761-769.
13. Dickerson, J. B.; Blackwell, J. E.; Ou, J. J.; Shinde Patil, V. R.; & Goetz, D. J. (2001). Limited adhesion of biodegradable microspheres to e- and p-selectin under flow. Biotechnology and Bioengineering, 73, 500-509.
14. Nguyen, K. T.; Shukla, K. P.; Moctezuma, M.; Braden, A. R.; Zhou, J.; Hu, Z.; et al. (2009). Studies of the cellular uptake of hydrogel nanospheres and microspheres by phagocytes, vascular endothelial cells, and smooth muscle cells. Journal of Biomedical Materials Research. Part A, 88, 1022-1030.
15. Lowenberg, E. C.; Meijers, J. C.; & Levi, M. (2010). Platelet-vessel wall interaction in health and disease. The Netherlands Journal of Medicine, 68, 242-251.
16. Deshayes, S.; Morris, M. C.; Divita, G.; & Heitz, F. (2005). Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cellular and Molecular Life Sciences, 62, 1839-1849.
17. Morris, M. C.; Deshayes, S.; Heitz, F.; & Divita, G. (2008). Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biology of the Cell, 100, 201-217.
18. Romo, G. M.; Dong, J. F.; Schade, A. J.; Gardiner, E. E.; Kansas, G. S.; Li, C. Q.; et al. (1999). The glycoprotein Ib-IX-V complex is a platelet counterreceptor for p-selectin. The Journal of Experimental Medicine, 190, 803-813.
19. Kim, D. H.; & Martin, D. C. (2006). Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials, 27, 3031-3037.
20. Xu, H.; Deshmukh, R.; Timmons, R.; & Nguyen, K. T. (2011). Enhanced endothelialization on surface modified poly(l-lactic acid) substrates. Tissue Engineering. Part A, 17, 865-876.
21. Kona, S.; Dong, J. F.; Liu, Y. L.; Tan, J. F.; & Nguyen, K. T. (2012). Biodegradable nanoparticles mimicking platelet binding as a targeted and controlled drug delivery system. International Journal of Pharmaceutical, 423, 516-524.
22. Lin, A.; Sabnis, A.; Kona, S.; Nattama, S.; Patel, H.; Dong, J. F.; et al. (2010). Shear-regulated uptake of nanoparticles by endothelial cells and development of endothelial-targeting nanoparticles. Journal of Biomedical Materials Research. Part A, 93, 833-842.
23. Xu, H.; Nguyen, K. T.; Brilakis, E. S.; Yang, J.; Fuh, E.; & Banerjee, S. (2012). Enhanced endothelialization of a new stent polymer through surface enhancement and incorporation of growth factor-delivering microparticles. Journal of Cardiovascular Translation, 5, 519-527.
24. Larifla, L.; Deprez, I.; Pham, I.; Rideau, D.; Louzier, V.; Adam, M.; et al. (2012). Inhibition of vascular smooth muscle cell proliferation and migration in vitro and neointimal hyperplasia in vivo by adenoviral-mediated atrial natriuretic peptide delivery. The Journal of Gene Medicine, 14, 459-467.
25. Kimura, S.; Egashira, K.; Nakano, K.; Iwata, E.; Miyagawa, M.; Tsujimoto, H.; et al. (2008). Local delivery of imatinib mesylate (sti571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation. Circulation, 118, S65-S70.
26. Mei, L.; Sun, H.; Jin, X.; Zhu, D.; Sun, R.; Zhang, M.; et al. (2007). Modified paclitaxel-loaded nanoparticles for inhibition of hyperplasia in a rabbit arterial balloon injury model. Pharmaceutical Research, 24, 955-962.
27. Bonan, R.; Paiement, P.; Scortichini, D.; Cloutier, M. J.; & Leung, T. K. (1993). Coronary restenosis: evaluation of a restenosis injury index in a swine model. American Heart Journal, 126, 1334-1340.
28. Feng, S. S.; Zeng, W.; Teng Lim, Y.; Zhao, L.; Yin Win, K.; Oakley, R.; et al. (2007). Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment. Nanomedicine (London, England), 2, 333-344.
29. Westedt, U.; Kalinowski, M.; Wittmar, M.; Merdan, T.; Unger, F.; Fuchs, J.; et al. (2007). Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment. Journal of Controlled Release, 119, 41-51.
30. Kamath, K. R.; Barry, J. J.; & Miller, K. M. (2006). The taxus drug-eluting stent: a new paradigm in controlled drug delivery. Advanced Drug Delivery Reviews, 58, 412-436.
31. Jain, A. K.; Das, M.; Swarnakar, N. K.; & Jain, S. (2011). Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Critical Reviews in Therapeutic Drug Carrier Systems, 28, 1-45.
32. Petros, R. A.; & DeSimone, J. M. (2010). Strategies in the design of nanoparticles for therapeutic applications. Nature Reviews. Drug Discovery, 9, 615-627.
33. Peracchia, M. T.; Vauthier, C.; Puisieux, F.; & Couvreur, P. (1997). Development of sterically stabilized poly(isobutyl 2-cyanoacrylate) nanoparticles by chemical coupling of poly(ethylene glycol). Journal of Biomedical Materials Research, 34, 17-26.
34. Betancourt, T.; Byrne, J. D.; Sunaryo, N.; Crowder, S. W.; Kadapakkam, M.; Patel, S.; et al. (2009). Pegylation strategies for active targeting of PLA/PLGA nanoparticles. Journal of Biomedical Materials Research. Part A, 91, 263-276.
35. Andrews, R. K.; & Berndt, M. C. (2004). Platelet physiology and thrombosis. Thrombosis Research, 114, 447-453.
36. Ni, H.; & Freedman, J. (2003). Platelets in hemostasis and thrombosis: role of integrins and their ligands. Transfusion and Apheresis Science, 28, 257-264.
37. Zou, X. Y.; Patil, V. R. S.; Dagia, N. M.; Smith, L. A.; Wargo, M. J.; Interliggi, K. A.; et al. (2005). Psgl-1 derived from human neutrophils is a high-efficiency ligand for endothelium-expressed e-selectin under flow. American Journal Physiological-Cell Ph, 289, C415-C424.
38. Eniola, A. O.; & Hammer, D. A. (2005). Characterization of biodegradable drug delivery vehicles with the adhesive properties of leukocytes II: effect of degradation on targeting activity. Biomaterials, 26, 661-670.
39. Blackwell, J. E.; Dagia, N. M.; Dickerson, J. B.; Berg, E. L.; & Goetz, D. J. (2001). Ligand coated nanosphere adhesion to e- and p-selectin under static and flow conditions. Annals of Biomedical Engineering, 29, 523-533.
40. Smith, C. A.; de la Fuente, J.; Pelaz, B.; Furlani, E. P.; Mullin, M.; & Berry, C. C. (2010). The effect of static magnetic fields and tat peptides on cellular and nuclear uptake of magnetic nanoparticles. Biomaterials, 31, 4392-4400.
41. Medintz, I. L.; Pons, T.; Delehanty, J. B.; Susumu, K.; Brunel, F. M.; Dawson, P. E.; et al. (2008). Intracellular delivery of quantum dot-protein cargos mediated by cell penetrating peptides. Bioconjugate Chemistry, 19, 1785-1795.
42. Zhang, K.; Fang, H.; Chen, Z.; Taylor, J. S.; & Wooley, K. L. (2008). Shape effects of nanoparticles conjugated with cell-penetrating peptides (HIV Tat PTD) on CHO cell uptake. Bioconjugate Chemistry, 19, 1880-1887.
43. Foerg, C.; & Merkle, H. P. (2008). On the biomedical promise of cell penetrating peptides: limits versus prospects. Journal of Pharmaceutical Sciences, 97, 144-162.
44. Torchilin, V. P. (2008). Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers, 90, 604-610.
45. Tsourkas, A.; Shinde-Patil, V. R.; Kelly, K. A.; Patel, P.; Wolley, A.; Allport, J. R.; et al. (2005). In vivo imaging of activated endothelium using an anti-VCAM-1 magnetooptical probe. Bioconjugate Chemistry, 16, 576-581.